smartQare exhibited at ESICM LIVES 2026, the 39th Annual Congress of the European Society of Intensive Care Medicine, in Lisbon, Portugal, from 12 to 14 October 2026.

We attended to demonstrate how continuous vital sign measurements can extend clinical visibility from the ICU into the general ward and, where appropriate, into the home.

At our booth, one question came up repeatedly: what happens to monitoring when patients move to the ward? Monitoring practices change after ICU discharge, but the need to follow how a patient is progressing does not.

Beyond the ICU

When a patient leaves the ICU, continuous monitoring usually gives way to manual checks by nursing staff already managing a full patient load. Each check shows a patient's condition at that moment, but not how it changes in between. That gap is not a lack of attention, but a limit of intermittent measurements.

For nurses, the challenge is having enough meaningful information to monitor patients without adding more manual work. For patients, it is maintaining visibility of their condition as they move between care settings.

smartQare's approach is designed to provide continuous patient information while reducing reliance on manual spot checks and supporting monitoring across the care pathway.

Continuous monitoring on the general ward

A patient's condition can change between routine checks. viQtor supports closing that gap. This wearable device measures pulse rate, respiratory rate, oxygen saturation (SpO₂), activity and posture automatically.

smartQare's hospital-to-home solutions extend that same principle beyond the hospital, so care teams can keep following patients as they recover at home.

What makes continuous data usable

Measuring vital signs continuously is only useful if the data reaches clinicians in a form they can use. In practice, three conditions matter.

  • Data quality. Continuous measurement gives clinical teams an ongoing, complete picture of how a patient's condition develops over time.
  • Connectivity. viQtor sends data directly over the mobile network, with no need for hubs, gateways or extra equipment at the bedside.
  • Integration. viQtor is designed to integrate with existing hospital systems, so data appears where clinicians already work and fit into current workflows.

Together, these elements form the foundation of the smartQare ecosystem, connecting high-quality clinical data, built-in connectivity and integration with existing hospital systems across the patient care pathway: from the ICU to ward to home.

Why this congress

Precision in clinical care and practice-changing science were central themes at this year’s congress.

Precision starts with the quality and continuity of the information available to healthcare teams. A single vital sign reading provides a snapshot at one moment; continuous data shows the trend of how values change over time and what that means for the patient's condition.

New approaches only become standard practice when evidence supports them. The viQtor is being used and evaluated in real clinical settings, where research is exploring how continuous measurement can support earlier recognition of deterioration on the general ward and inform decisions about the right level of care.

Clinical evidence from Erasmus MC

Erasmus MC (Rotterdam, the Netherlands) presented a study at this year's congress on continuous vital sign monitoring with viQtor after ICU discharge.

The study, Continuous Vital Sign Monitoring After ICU Discharge: Real-World Ward Performance, Measurement Agreement, and Patient Acceptability of a Wearable Sensor, followed 180 patients for up to five days after ICU discharge. It looked at three questions that come before any clinical outcome: whether a wearable sensor produces usable data in routine ward care, the level of measurement agreement and whether patients are willing to wear it.

The study yielded 14,741 hours of monitoring data, with an overall data availability of 98.5%. All parameters showed positive associations with nurse-measured values, and patient-reported acceptability was high, with 79.2% of patients reporting a neutral or positive attitude toward future use. The full abstract, including the measurement agreement results, is available in the ESICM LIVES 2026 programme.

Continuing the conversation

We would like to thank everyone who visited the smartQare booth and shared their experiences, challenges and perspectives during ESICM LIVES 2026.

To learn more about smartQare's wearable monitoring solutions and clinical evidence, contact our team or explore our clinical resources.

The smartQare team at ESICM LIVES 2026 in Lisbon.